Australia's Arovella Therapeutics falls on ending collaboration with Imugene

Imugene

20/03/2024 01:39

** Shares of Arovella Therapeutics  ALA.AX  down as much as
14.5% at A$0.133, their lowest since Jan. 30
    ** Cancer therapy developer says Imugene  IMU.AX  has
terminated its research collaboration with co 
    ** Says collaboration was to combine its blood cancer
therapy ALA-101 with IMU's onCARlytics platform
    ** IMU shares drop as much as 4.6% to A$0.105
    ** About 3.1 mln ALA shares change hands, compared with
30-day average volume of around 1.9 mln
    ** ALA stock flat YTD, based on last close



 (Reporting by Aaditya Govind Rao in Bengaluru)
 ((Aaditya.govindrao@thomsonreuters.com;))